PEIJIA-B (09996) saw its shares rise more than 6% during the trading session. As of the time of writing, the stock was up 3.83%, trading at HK$6.5, with a turnover of HK$3.5234 million. On April 9, PEIJIA-B announced that the first patient implantation of the GeminiOne® Transcatheter Edge-to-Edge Repair (TEER) system in the U.S. Food and Drug Administration (FDA) Early Feasibility Study (EFS) has been successfully completed. The procedure was performed by Professor Saibal Kar, Director of Structural Heart Intervention and Clinical Research at Los Robles Regional Medical Center, part of HCA Healthcare, and Clinical Professor of Medicine at the David Geffen School of Medicine at UCLA. A previous research report from CICC noted that PEIJIA-B's valve business revenue for 2025 reached 290 million yuan, a year-on-year increase of 11.6%, marking the first time the valve business has achieved a positive contribution. The company's third-generation long-lasting dry valve, TaurusNXT, was accepted by the NMPA in December 2025, while the GeminiOne TEER system has submitted a registration application in China and is simultaneously advancing its EU MDR CE application. The HighLife TMVR registration clinical trials are also progressing steadily.